NCT05083364 - Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

May 5, 2025

Study Completion Date

September 30, 2025

Conditions

C3 GlomerulopathyIgA Nephropathy

Interventions

DRUG

ARO-C3

ARO-C3 for sc injection

DRUG

Placebo

sterile normal saline (0.9% NaCl) for sc injection

Trial Locations (16)

1010

Research Site, Auckland

2050

Research Site 1, Camperdown

2139

Research Site 3, Concord

3168

Research Site 2, Clayton

10400

Research Site 2, Bangkok

10444

Research Site 4, Goyang-si

42601

Research Site 3, Daegu

48108

Research Site 2, Haeundae

49267

Research Site 1, Gamcheon

50200

Research Site 3, Chiang Mai

50937

Research Site 2, Cologne

91054

Research Site 4, Erlangen

0112

Research Site 2, Tbilisi

03722

Research Site 6, Soeul

05030

Research Site 8, Soeul

OX3 7LE

Research Site 4, Oxford